Blogs

The following disclaimer applies to the Draft Red Herring Prospectus (“DRHP”) filed by 20 Microns Nano Minerals Limited (“the Company”) on the SME Platform of the National Stock Exchange of India Limited (“NSE EMERGE”)hosted on this website in connection with the proposed initial public offering of the Company’s Equity Shares (“the Issue“). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the DRHP. By accessing the DRHP, you agree to abide by the following terms and conditions, including any modifications from time to time.

The Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its equity shares (the “Issue”) and has prepared and filed its draft red herring prospectus for the purpose of such Issue with the NSE EMERGE on March 22, 2018. The draft red herring prospectus is available on the website of NSE EMERGE at https://www.nseindia.com/emerge and the website of the Book Running Lead Manager at www.vivro.net. You should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled “Risk Factors” of the aforementioned offer document.

The contents of the DRHP are for your information only. The Company and/or its affiliates are not soliciting any action based on it, and it should not be construed as an offer to sell or the solicitation of any offer to buy or subscribe for any security and should not be construed as such. The Company does not represent that the content of the DRHP is complete or comprehensive beyond the date of its filing with NSE EMERGE and does not guarantee the accuracy, timeliness or completeness of the information being made available to you in the DRHP beyond that date.
The information in this section is directed at, and is intended for distribution to, and use by, residents of India or residents of permitted jurisdictions only. Residents of countries where distribution/viewing of such information is not permitted, are not authorized to view or use the information in this section. Please note that because of restrictions imposed by law on soliciting securities business in various jurisdictions, subscription to the Issue will not be permitted to residents of certain jurisdictions. The DRHP is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company, BRLM or any of its Affiliates would by virtue of such distribution become subject to new or additional registration requirements.

No part of the contents herein shall be copied or duplicated in any form by any means or redistributed in whole or in part and in particular, may not be forwarded to any U.S. person or to any U.S. address or any other jurisdictions where such distribution is not permitted. Any forwarding, distribution or reproduction of the contents herein, in whole or in part, is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the applicable laws of other jurisdictions. The Equity Shares of the Company have not been and will not be registered under the Securities Act, as amended and may not be offered or sold within the United States (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. There will not and is not currently intended to be any public offering of securities in the United States. Accordingly, the Equity Shares are only being offered and sold outside the United States in reliance on Regulation S of the Securities Act and the applicable laws of the jurisdiction where these offer and sales occur.